High xCT expression has been proposed as a biomarker for glioma‐related epilepsy, independent of IDH mutation status, with IDHwt tumors exhibiting higher xCT levels than their mutated counterparts [9]. The gene discussed is IDH1; the disease is central nervous system cancer.